Prospective evaluation of vedolizumab-effects and safety in patients with inflammatory bowel diseases (VED IBD Cohort Study)

Prospective evaluation of vedolizumab-effects and safety in patients with inflammatory bowel diseases (VED IBD Cohort Study) - VED IBD Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040175

Enrollment

Registered

2020-05-11

Start date

2020-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis and Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with inflammatory bowel diseases,such as ulcerative colitis and Crohn7s disease treated with vedolizumab

Exclusion criteria

Exclusion criteria: 1. Patients without informed consent 2. Patients determined to be inappropriate by doctor

Design outcomes

Primary

Measure	Time frame
Persistence of vedolizumab at week 54	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results